Drug Profile
BMN 293
Alternative Names: BMN-293; DiNA-001; DINA-001/A; DINA-001/BLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator DiNAQOR AG
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference; Myosin-binding protein C replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertrophic cardiomyopathy
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Hypertrophic-cardiomyopathy in Switzerland (Intracardiac)
- 11 Nov 2023 Pharmacodynamics data from a preclinical study in Hypertrophic cardiomyopathies presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
- 25 Feb 2022 BioMarin Pharmaceutical intends to file an IND application for Hypertrophic cardiomyopathy in second half of 2023